Literature DB >> 18472638

FTY720 treatment in experimentally urethane-induced lung tumors.

Léa Bueno Lucas da Silva1, Daniel Araki Ribeiro, Patrícia Maluf Cury, José Antonio Cordeiro, Valquiria Bueno.   

Abstract

FTY720 has been shown to prevent cancer development in experimental models but there is no report whether this beneficial effect is associated with the time point of the drug administration. Lung adenoma was induced in mice by urethane injection followed by different periods of FTY720 administration in order to evaluate lung tumor development. BALB/c mice received two doses (1, 5 g/kg) of urethane intraperitoneally and were submitted to five daily doses of FTY720 (1 mg/kg/day) starting just after urethane injection (G2 n=5), 4 weeks after urethane injection (G3 n=10), 8 weeks after urethane injection (G4 n=10) and no FTY720 administration (G1 n=5). Twenty-four weeks after urethane administration mice were evaluated for leukocyte numbers in blood, lymphocytes in spleen, and lungs were evaluated for changes in histology and PCNA expression. Lung nodules were present in higher numbers both in non treated (G1; 0.0-7.0) and FTY720 treated 8 weeks after urethane injection (G4; 0.0-6.0). G4 Group also presented the highest number of papillary nodules. There was a decrease in PCNA staining in early time FTY720 treated mice. Therefore, our data suggest that FTY720 treatment in early periods after lung tumor induction is beneficial and impairs adenoma development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472638

Source DB:  PubMed          Journal:  J Exp Ther Oncol        ISSN: 1359-4117


  6 in total

Review 1.  Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Authors:  Roger A Sabbadini
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 2.  Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.

Authors:  Suriyan Ponnusamy; Marisa Meyers-Needham; Can E Senkal; Sahar A Saddoughi; David Sentelle; Shanmugam Panneer Selvam; Arelis Salas; Besim Ogretmen
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

3.  Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720.

Authors:  Natália R Salinas; Camila T Lopes; Patrícia V Palma; Celina T Oshima; Valquiria Bueno
Journal:  Pathol Oncol Res       Date:  2009-02-12       Impact factor: 3.201

Review 4.  Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.

Authors:  Esther Melamed; Michael William Lee
Journal:  Front Immunol       Date:  2020-01-10       Impact factor: 7.561

Review 5.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26

Review 6.  Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer.

Authors:  Cassandra P Nader; Aylin Cidem; Nicole M Verrills; Alaina J Ammit
Journal:  Respir Res       Date:  2019-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.